Studies show that ozepic may reduce the risk of depression

Jab for joy?

A historical study of approximately 30,000 patients found that the use of GLP-1 drugs, which include Wegovy and Ozempic, may have “an antidepressant” effect, suggesting that these medicines can be used one day in mental health therapy.

And while some people may have a promotion of mental health and self-images by losing weight, it is not really what scholars think is the cause.

Semaglutide – active ingredient in ozepic And Wegovy-is part of a class of drugs that mimic the Natural Hormone of the GLP-1 body, making the user feel fuller for longer.

Originally developed to treat type 2 diabetes, GLP-1 drugs have become extremely popular because of their ability to help people lose weight by slowing down digestion and reducing appetite. Since the market flood, a multitude, have been reported additional health benefits.

Recent studies have shown medicines like Wegovy and Ozepic can help fight kidney disease and can be useful in preventing and treating substances abuse.

In a clinical test, the use of Wegovy was related to the improved ability to exercise in people with diabetes and heart failure. Last March, Wegovy was approved to reduce the risk of stroke, heart attacks and other serious cardiovascular problems in patients who are overweight or overweight.

Preliminary research has also suggested that semaglutide can protect against neurodegeneration and neuroinflammation, which means medicines as ozempic can potentially protected against Alzheimer’s.

Now add increased happiness can be added to the increasing list of GLP-1 medication-related health benefits.

According to the centers for disease control and prevention, nearly one in five adults in the JSC are diagnosed with depression, which is believed to arise from a combination of genetic background and environmental stressors.

Further, patients with type 2 diabetes are about twice as likely to be diagnosed with depression compared to others.

Although numerous anti-depressant treatments are currently available, a 30% startling 30% of depression-diagnosed patients do not suffer positive therapeutic effects with these established treatments.

In the latest study, published in the American Journal of Geriatric Psychiatry, a research team at the University of Florida compared depression in diabetics over the age of 66, who were being treated with GLP-1 drugs and those attending a different course of treatment.

Scientists found that patients receiving GLP-1ras reported fewer symptoms of depression than those in the usual diabetes of dipeptidil peptidaza-4 inhibitors (DPP4IS), also collectively known as gliptins.

Researchers concluded that this showed that medicines could have a beneficial effect on depression.

The team noted that their findings are not generally general for new or diabetes.

However, this latest study seems to support previous research that found that GLP-1 drugs can improve mental health and reduce the risk of suicide in adolescents.

These findings contradict previous concerns about drug potential as ozepic to cause suicide ideas and self-harming in children and adults.

Experts believe that the efficiency of these drugs in reducing the risk of depression lies in reducing inflammation, as inflammatory responses and immunity are critical in the development and onset of depression.

Inflammation is the body’s natural response to the disease or damage. The body signals the immune system to send inflammatory cells to fight the disease or to help healing. However, if cells are sent when the body does not need them, it can promote chronic inflammation, which is known to be a symptom of some diseases, including Alzheimeria.

An inflammatory response within the brain – called neuroinflammation – can change nerve circuits, and may be causing, or intensifying depression. Research suggests that about 30% of depressed patients have raised inflammation.

GLP-1 drugs indirectly reduce inflammation through weight loss. MEDs can also activate certain cells white T-cells of the key to the immune system-which can have anti-inflammatory effects. GLP-1 has also been reported to promote the production of anti-inflammatory cytokines in various organs including the brain